NYKODE THERAPEUTICS ASA logo NYKODE THERAPEUTICS ASA

Selskapsinformasjon

Ticker: NYKD
Børsverdi: 1 121 MNOK
Nordnet 4 481
Avanza 583
Kommende hendelserHendelser ℹ️
Rapport: 27.05.2026
20.03.2026 14:45

Nykode Therapeutics Highlights Robust Immunogenicity and Promising Clinical Activity for Abi-Suva at ICHNO 2026

• Encouraging preliminary efficacy was observed, with a confirmed ORR of 38.5% (5 out of 13 PD-L1-positive patients) compared to 19.1% in the reported historical control with standard of care (pembrolizumab monotherapy) in a comparable first-line setting. In patients with high PD-L1 expression (CPS ...

Les hele pressemeldingen

Antall Eiere